Pilot study of an occupational healthcare program to assess the SARS-CoV-2 infection and immune status of employees in a large pharmaceutical company

Petra C. Moroni-Zentgrafa Human Pharma Medicine, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GermanyCorrespondence[email protected]

Christoph Kellerb HP Country Pharmacovigilance, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany

Mazyar Mahmoudic Human Pharmacology Centre, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany

Kimberley Kallsend Global Patient Advocacy Relations, Boehringer Ingelheim International GmbH, Ingelheim, Germany

Christoph C. Eschenfeldera Human Pharma Medicine, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany

Ralf Sigmunde Biostatistics and Data Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany

Hanns Walter Müllerf Non-clinical Statistics, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany

Patrick Baumg Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany

Bertram Boosh Occupational Health and Medical Services, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany

Michael Schneiderh Occupational Health and Medical Services, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany

Egbert Mundti New Biological Entities, Boehringer Ingelheim Animal Health France SCS, Saint-Priest, France

Your download is now in progress and you may close this window